Who are Experimental: Alpha-blocker group's main competitors?

Direct comparators (same drug class / molecular target / therapeutic area): Comparator: carvedilol, placebo; diphenhydramine/phenylephrine/cocoa; dextromethorphan, Norepinephrine intra-arteriel/hepatic, Brompheniramine + pseudoephedrine, alpha blocker monotherapy, Midodrine + pyridostigmine.

How often does this brief refresh?

Every 30 minutes from primary sources (FDA, EMA, MHRA, PMDA, ClinicalTrials.gov, USPTO). Subscribe to the RSS feed below for push alerts.

How do I get this as a recurring report?

Subscribe to /feed/ci/experimental-alpha-blocker-group.xml in any RSS reader (Feedly, Inoreader, NewsBlur). Every regulatory action, trial readout, or patent event lands in your feed automatically.

Last reviewed 2026-05-14 · How we verify

Experimental: Alpha-blocker group — Competitive Intelligence Brief

Experimental: Alpha-blocker group (Experimental: Alpha-blocker group) competitive landscape: 6 comparators, recent regulatory actions, upcoming PDUFA, patent timeline. Class: Alpha-blocker. Area: Cardiovascular; Urology.

marketed Alpha-blocker Alpha-1 adrenergic receptor Cardiovascular; Urology Small molecule Live · refreshed every 30 min

Target snapshot

Experimental: Alpha-blocker group (Experimental: Alpha-blocker group) — Pedro de Figueiredo Buchalla. Alpha-blockers inhibit alpha-adrenergic receptors on vascular smooth muscle and the prostate, causing vasodilation and reduced urinary obstruction.

Comparator set (6 drugs)

Auto-detected by same drug class / molecular target / therapeutic area, ranked by phase + recency. Override with ?vs=slug1,slug2,….

Drug	Generic	Sponsor	Phase	Class	Target
Experimental: Alpha-blocker group TARGET	Experimental: Alpha-blocker group	Pedro de Figueiredo Buchalla	marketed	Alpha-blocker	Alpha-1 adrenergic receptor
Comparator: carvedilol	Comparator: carvedilol	Organon and Co	marketed	Beta-blocker with alpha-1 antagonist activity	Beta-1 adrenergic receptor, Beta-2 adrenergic receptor, Alpha-1 adrenergic receptor
placebo; diphenhydramine/phenylephrine/cocoa; dextromethorphan	placebo; diphenhydramine/phenylephrine/cocoa; dextromethorphan	Montefiore Medical Center	marketed	Combination cold and cough remedy	H1 receptor (diphenhydramine); alpha-1 adrenergic receptor (phenylephrine); sigma-1 receptor and NMDA receptor (dextromethorphan)
Norepinephrine intra-arteriel/hepatic	Norepinephrine intra-arteriel/hepatic	University Health Network, Toronto	marketed	Sympathomimetic amine / Adrenergic agonist	Alpha-1 adrenergic receptor, Beta-1 adrenergic receptor
Brompheniramine + pseudoephedrine	Brompheniramine + pseudoephedrine	Ache Laboratorios Farmaceuticos S.A.	marketed	Antihistamine + decongestant combination	H1 receptor (brompheniramine); alpha-1 adrenergic receptor (pseudoephedrine)
alpha blocker monotherapy	alpha blocker monotherapy	Samsung Medical Center	marketed	Alpha blocker	alpha-1 adrenergic receptors
Midodrine + pyridostigmine	Midodrine + pyridostigmine	Seoul National University Hospital	marketed	Alpha-1 adrenergic agonist + acetylcholinesterase inhibitor combination	Alpha-1 adrenergic receptor; acetylcholinesterase

Recent regulatory actions (last 90 days)

No regulatory actions in the last 90 days for this set.

Upcoming PDUFA dates (next 180 days)

No PDUFA dates in the next 180 days for this set.

Patent timeline (forward window)

No upcoming patent expiries for this set.

Sponsor landscape (Alpha-blocker class)

Pedro de Figueiredo Buchalla · 1 drug in this class

Subscribe to ongoing alerts

Push every new event for this competitive set into your RSS reader, IFTTT/Zapier workflow, or email digest:

Cite this brief

Drug Landscape (2026). Experimental: Alpha-blocker group — Competitive Intelligence Brief. https://druglandscape.com/ci/experimental-alpha-blocker-group. Accessed 2026-05-14.

Build your own brief

Pick any drug + add comparators:

https://druglandscape.com/ci/{slug} — auto-detected competitors
https://druglandscape.com/ci/{slug}?vs=drug1,drug2,drug3 — explicit comparators
Brand names auto-resolve: /ci/keytruda → 301 → /ci/pembrolizumab